Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
Mindset Pharma (OTCQB: MSSTF) has received a Notice of Allowance from the USPTO for its patent application 17/387,845, focused on psilocin derivatives as psychedelic agents for CNS disorders. This patent, with a priority date of February 4, 2020, covers several second-generation drug candidates classified as 'Family 1,' which aim to improve pharmacokinetics and safety over existing treatments like psilocybin. CEO James Lanthier highlighted this milestone as a step towards strengthening the company's intellectual property and pipeline growth.
- Receipt of USPTO Notice of Allowance for patent application 17/387,845.
- Patent covers second-generation psilocin derivatives with potential therapeutic improvements.
- Strengthens Mindset's intellectual property portfolio with early priority date.
- None.
TORONTO, June 10, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Mindset’s patent application number 17/387,845, titled, “Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.” The patent carries a priority date of February 4, 2020.
Included within this application are several drug candidates that the Company classifies as belonging to its “Family 1” which are second-generation compounds with potential improvements compared to psilocybin in pharmacokinetics, effect size, safety, and manufacturing.
“This notice of allowance marks yet another important milestone in our pursuit of creating next generation psychedelic drugs to treat neurological and psychiatric disorders with unmet needs,” said James Lanthier, CEO of Mindset Pharma. “We are very pleased to further reinforce our robust intellectual property portfolio, especially with the advantage of an early priority date of February 2020 for this patent. This is a key step towards continued growth for Mindset and our developing pipeline of drug candidates.”
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
For more information, please contact:
Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585
Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FAQ
What does the USPTO Notice of Allowance mean for Mindset Pharma (OTCQB: MSSTF)?
What is the priority date for Mindset Pharma's newly granted patent?
What are the implications of the new patent for Mindset Pharma's drug candidates?
How does the new patent impact Mindset Pharma's growth strategy?
